公开(公告)号：US5434135A

公开(公告)日：1995-07-18

申请号：US008641

申请日：1993-01-25

申请人： Indu Parikh ,  Ronald Nardi ,  Tanchum Amarant ,  Antonio Guglietta

发明人： Indu Parikh ,  Ronald Nardi ,  Tanchum Amarant ,  Antonio Guglietta

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/22 ,  A61P43/00 ,  C07K1/18 ,  C07K14/37 ,  C07K14/41 ,  C07K14/485 ,  C07K14/52 ,  C12P21/02 ,  C12R1/84

CPC分类号： C07K14/485 ,  A61K38/00

摘要： The invention in growth factor compositions includes: a novel compound which is a separate pure nicked or pure non-nicked species of epidermal growth factor EGF1-48 or its hEGF1-47 or hEGF1-49 congener compound, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition in dosage form comprising an effective amount of the novel compound and/or the known hEGF1-53; and use thereof for treating abnormal cell growth conditions including gastrointestinal/duodenal lesions; and methods of making the pure novel hEGF species. This unique therapeutic utility is enhanced by the unexpected and heretofore unappreciated structural stability and resistance of the pure species to enzymatic degradation.

摘要翻译： 本发明在生长因子组合物中包括：一种新型化合物，其为分离的纯切口或纯非切口的表皮生长因子EGF1-48或其hEGF1-47或hEGF1-49同源化合物或其药学上可接受的盐; 包含有效量的新化合物和/或已知的hEGF1-53的剂型药物组合物; 及其用于治疗包括胃肠/十二指肠损伤的异常细胞生长条件的用途; 以及制作纯新型hEGF物种的方法。 这种独特的治疗效用通过意想不到的和迄今为止尚未被欣赏的结构稳定性和纯物质对酶降解的抗性而增强。